Study study type PathologyT1T0Patientssample sizesROB Results

la/mBC - HR positive - (neo)adjuvant (NA) breast cancer - HR positive la/mBC - HR positive la/mBC - HR positive - (neo)adjuvant (NA)

versus letrozole
alpelisib plus letrozole
NEO-ORB (mutant cohort), 2019
  NCT01923168
RCTla/mBC - HR positive - (neo)adjuvant (NA)alpelisib plus letrozoleletrozolePostmenopausal women with locally confirmed, HR , HER2−, T1c-T3 operable breast cancer with known PIK3CA mutation status, who had not previously received treatment with local or systemic therapy and were considered eligible for neoadjuvant endocrine therapy were included in this study.-/-NA
inconclusive
  • inconclusive 6 % decrease in objective responses (ORR) (PE)
  • inconclusive 45 % decrease in pCR (PE)
NEO-ORB (wild type cohort), 2019
  NCT01923168
RCTla/mBC - HR positive - (neo)adjuvant (NA)alpelisib plus letrozoleletrozolePostmenopausal women with locally confirmed, HR , HER2−, T1c-T3 operable breast cancer with known PIK3CA mutation status, who had not previously received treatment with local or systemic therapy and were considered eligible for neoadjuvant endocrine therapy were included in this study.131 / 126NA
inconclusive
  • inconclusive 11 % increase in objective responses (ORR) (PE)
  • inconclusive 68 % increase in pCR (PE)

la/mBC - HR-positive - 2nd line (L2) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2)

versus fulvestrant
alpelisib plus fulvestrant
SOLAR-1 (patients without PIK3CA mutant status), 2019
  NCT02437318
RCTla/mBC - HR-positive - 2nd line (L2)alpelisib plus fulvestrantplacebo plus fulvestrantPatients were men and postmenauposal women with locally advanced confirmed HR positive, HER2 negative breast cancer / Patient has recurrence or progression of disease during or after AI therapy115 / 116low
inconclusive
  • inconclusive 15 % decrease in progression or deaths (PFS) (PE)
SOLAR-1 (patients with PIK3CA mutant status), 2019
  NCT02437318
RCTla/mBC - HR-positive - 2nd line (L2)alpelisib plus fulvestrantplacebo plus fulvestrantPatients were men and postmenauposal women with locally advanced confirmed HR positive, HER2 negative breast cancer169 / 172low
conclusif
  • inconclusive 14 % decrease in deaths (OS) (PE)
  • demonstrated 35 % decrease in progression or deaths (PFS) (PE)